Related Experiment Video
Updated: Jul 29, 2025
05:45
Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
Published on: July 31, 2017
9.7K
Macrophages in the Glioblastoma Tumor Microenvironment
1Department of Biological Sciences, School of Integrative Science and Technology, Kean University, Union, NJ 07083, USA.
International Journal of Molecular Sciences
|May 27, 2023
Abstract:
The prognosis of high-grade glioma remains dismal, with the median survival time being 15 months [...].
Insights
High-grade glioma has a poor prognosis, with a median survival of only 15 months. This highlights the urgent need for improved treatment strategies for this aggressive brain cancer.
Area of Science:
- Neuro-oncology
- Cancer research
- Clinical neurology
Background:
- High-grade glioma (HGG) presents a significant challenge in neuro-oncology.
- Current treatment protocols offer limited efficacy, resulting in a dismal prognosis.
- The median survival time for HGG patients remains critically short at approximately 15 months.
Discussion:
- The limited survival underscores the aggressive nature of high-grade gliomas.
- Investigating novel therapeutic targets is crucial for improving patient outcomes.
- Understanding the molecular underpinnings of HGG is essential for developing effective treatments.
Key Insights:
- The prognosis for high-grade glioma is exceptionally poor.
- Median survival rates have seen minimal improvement over time.
- There is a critical unmet need for advanced therapeutic interventions.
Outlook:
- Future research should focus on innovative treatment modalities.
- Developing targeted therapies based on glioma subtypes may offer new hope.
- Continued investigation into the biology of HGG is paramount for advancing patient care.
